StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Valeant Pharmaceuticals (VRX) PT Lowered to $18 at Jefferies
March 1, 2017 7:46 AM
Jefferies lowered its price target on Valeant Pharmaceuticals (NYSE: VRX) to $18.00 (from $22.00) while maintaining a Buy rating following ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
UPDATE: Valeant Pharmaceuticals (VRX) PT Lowered to $19 at BMO Capital Following 4Q Results; 'Entering Transitional Period'
March 1, 2017 6:09 AM
Valeant Pharmaceuticals (VRX) PT Lowered to $21 at RBC Capital
March 1, 2017 5:46 AM
Guggenheim Reiterates Buy Rating and $55 PT on Valeant Pharmaceuticals (VRX) Following 4Q Beat; 'Growth Prospects Underappreciated'
February 28, 2017 3:30 PM
Mizuho Securities Maintains Underperform Rating on Valeant Pharmceuticals (VRX); 'Weaker 2017 EBITDA Outlook'
February 28, 2017 8:54 AM
Valeant predicts tough 2017 with revenue to decline
February 28, 2017 8:40 AM
RBC Capital Maintains Sector Perform Rating and $22 PT on Valent Pharmaceuticals (VRX) Following Q4 Results, 2017 'Guidance Lower than Street'
February 28, 2017 7:42 AM
Valeant Pharma (VRX) Tops Q4 EPS by 5c; Guides In-Line
February 28, 2017 7:04 AM
Form 8-K Valeant Pharmaceuticals For: Feb 28
February 28, 2017 7:02 AM
Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance
February 28, 2017 7:00 AM
